This study investigates how PI3K enables pancreatic cancer cells to resist KRAS inhibitors by activating wild-type RAS signaling, suggesting combined PI3K-KRAS targeting as a therapeutic strategy.
This study investigates how PSMA-PET imaging for prostate cancer leads to earlier use of advanced therapies compared to traditional bone scans, impacting treatment decisions and costs.
This study investigates biomarkers in renal cell carcinoma, showing tumor PD-L1 expression predicts better survival with immunotherapy, while neutrophil markers highlight sarcomatoid/rhabdoid tumor immune environments.
This study investigates advances in minimally invasive therapies for lung cancer, showing improved tumor targeting, safety, and potential benefits when combined with immunotherapy and chemotherapy.